Roche latest to hold back on US drug price hikes

23 July 2018

Joining US pharma majors Pfizer and Merck & Co, as well as Europe’s Bayer, Merck KGaA, Novartis and Sanofi, Swiss pharma giant Roche (ROG: SIX) is the latest company to announce its restraint on drug pricing and price hikes in the USA.

Roche on Friday revealed that, the previous week, it communicated to the US Department of Health and Human Services (HHS) that it will not be taking any price increases for the remainder of the year.

However, according to a Reuters report, some analysts doubt such freezes would have much overall impact, however, since the companies’ pledges may take them out of US President Donald Trump’s immediate firing line while still leaving leeway to resume increases in 2019.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK